| REVENUE |
REVENUE The following table presents the Company’s revenue disaggregated by geographic areas based on the customers’ locations: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | (in thousands) | September 30, 2026 | | September 30, 2025 | | September 30, 2026 | | September 30, 2025 | | United States | | | | | | | | | Screening | $ | 36,143 | | | $ | 32,570 | | | $ | 116,316 | | | $ | 95,482 | | | Development Services | — | | | 78 | | | 200 | | | 332 | | International(1) | | | | | | | | | Screening | 1,126 | | | 237 | | | 3,427 | | | 837 | | | Development Services | 266 | | | 3,309 | | | 3,064 | | | 6,924 | | | Total | $ | 37,535 | | | $ | 36,194 | | | $ | 123,007 | | | $ | 103,575 | | (1) International region includes revenue earned from customers located outside of the United States.The following table presents the Company’s revenue disaggregated by revenue source: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | (in thousands) | September 30, 2026 | | September 30, 2025 | | September 30, 2026 | | September 30, 2025 | | Screening | | | | | | | | | Commercial | $ | 34,801 | | | $ | 31,428 | | | $ | 112,250 | | | $ | 93,681 | | Government(1) | 2,468 | | | 1,379 | | | 7,493 | | | 2,638 | | | Development Services | | | | | | | | | Commercial | 266 | | | 3,387 | | | 3,264 | | | 7,256 | | | | | | | | | | | Total | $ | 37,535 | | | $ | 36,194 | | | $ | 123,007 | | | $ | 103,575 | |
(1) Government screening revenue primarily consists of revenue earned as part of our REACH/Galleri-Medicare clinical study.
|